Welcome to our dedicated page for Immunocore Holdings Plc SEC filings (Ticker: IMCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunocore Holdings plc (IMCR) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a Nasdaq‑listed foreign private issuer. Immunocore files current reports on Form 8‑K, annual reports on Form 10‑K and other documents that describe its financial performance, risk factors, capital structure and progress across its ImmTAX platform in oncology, infectious diseases and autoimmune diseases.
Recent Form 8‑K filings dated August 7, 2025 and November 6, 2025 report the release of quarterly financial results and business updates, including net product sales from KIMMTRAK, cash and marketable securities, and status of key clinical trials such as TEBE‑AM, PRISM‑MEL‑301 and ATOM. These filings also incorporate press releases as exhibits, giving additional detail on KIMMTRAK approvals, launches and the company’s pipeline of ImmTAC, ImmTAV and ImmTAAI candidates.
On this page, investors can review Immunocore’s periodic reports to understand how the company accounts for revenue from its commercial product, funds research on TCR bispecifics for HIV and HBV, and advances autoimmune programs like IMC‑S118AI and IMC‑U120AI. Form 4 and related insider transaction filings, when available, can be used to track equity dealings by directors and senior stakeholders.
Stock Titan enhances these IMCR filings with AI‑powered summaries that highlight key points from lengthy documents, helping readers quickly identify information on KIMMTRAK commercialization, clinical trial commitments, liquidity, and material events disclosed under U.S. securities laws, while still allowing access to the full original SEC text for detailed analysis.
Immunocore Holdings Plc reported an insider sale. A holder executed a same-day cashless exercise and sale of 11,832 ADRs on 03/11/2026, with cash proceeds. The filing also records an earlier sale of 5,965 ADRs on 02/18/2026.
T. Rowe Price Investment Management, Inc. amended a Schedule 13G to report beneficial ownership of 3,041,904 ADRs of IMMUNOCORE HOLDINGS PLC as of 02/28/2026, representing 6.0% of the class. The filing lists sole voting and dispositive power over 3,041,904 ADRs.
The filing includes a signature dated 03/06/2026 and a statement denying beneficial ownership. No transaction price, purchase/sale direction, or cash‑flow details are provided in the excerpt.
Immunocore Holdings reported strong 2025 growth from its lead therapy KIMMTRAK while remaining modestly loss-making. KIMMTRAK net sales reached $400.0 million for 2025, up from $310.0 million in 2024, with Q4 2025 sales of $104.5 million versus $84.1 million a year earlier.
Full-year net loss narrowed to $35.5 million from $51.1 million, or $0.71 per share versus $1.02. The company increased investment in its pipeline, with 2025 R&D expenses of $274.9 million and SG&A of $165.4 million. Cash, cash equivalents and marketable securities were $864.2 million as of December 31, 2025.
Management highlighted 15 consecutive quarters of KIMMTRAK revenue growth and ongoing global launches in uveal melanoma, while advancing multiple Phase 3 trials in melanoma, PRAME-targeted programs in solid tumors, an HIV functional cure program, and first autoimmune candidates, with key data readouts anticipated in the second half of 2026.
Immunocore Holdings plc is a commercial-stage biotech company built on its ImmTAX bispecific TCR platform, aiming to treat cancer, infectious and autoimmune diseases. Its first product, KIMMTRAK, is approved for metastatic uveal melanoma in 39 countries and launched commercially in 30.
In 2025, revenue from sale of therapies reached $400.0 million, up from $310.0 million in 2024, driven mainly by the United States at $257.0 million, with Europe contributing $131.4 million and international markets $11.6 million. As of January 31, 2026, Immunocore had 50,695,078 ordinary shares outstanding.
The company is running multiple late-stage oncology trials, including three Phase 3 studies for KIMMTRAK and PRAME‑targeted brenetafusp, and advancing infectious disease candidates for HIV and hepatitis B as well as new autoimmune programs IMC‑S118AI and IMC‑U120AI. Management highlights ongoing losses, funding needs, competitive pressures, regulatory risk and IP challenges as key risk factors.
Coy Travis Alan reported acquisition or exercise transactions in this Form 4 filing.
Immunocore Holdings plc reported that Chief Financial Officer Travis Alan Coy received new equity awards. On February 17, 2026, he was granted 33,353 Restricted Share Units, each representing a contingent right to receive one Ordinary Share, which vest in four equal annual installments starting February 17, 2027, subject to continuous service.
He was also granted an option over 95,637 shares, with 25% vesting on February 17, 2027 and 6.25% vesting in quarterly installments thereafter, also subject to continuous service. Ordinary Shares may be represented by American Depositary Shares, with each ADS equal to one Ordinary Share.
Immunocore Holdings plc chief executive officer Bahija Jallal reported several equity transactions. She sold 11,474 Ordinary Shares in an open-market transaction at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to pay income taxes triggered by vesting restricted share units.
On a separate date, she acquired 23,817 Ordinary Shares at no cost through the exercise of Restricted Share Units, with each RSU converting into one Ordinary Share. She was also granted 88,573 new RSUs and 395,066 employee share options, each award vesting in scheduled installments starting in February 2026 or February 2027, contingent on continued service.
Immunocore Holdings plc executive John Goll reported both equity awards and a small tax-related share sale. As SVP, Finance & CAO, he sold 698 Ordinary Shares on February 18, 2026 in an open-market transaction at a weighted average price of $32.35 per share under a sell-to-cover arrangement to satisfy income tax liabilities from vesting restricted share units (RSUs).
On February 17, 2026, he acquired 1,351 Ordinary Shares through the exercise of RSUs, and received grants of 7,411 additional RSUs and 21,252 employee share options. The new RSUs and options vest in equal annual and quarterly installments beginning in February 2027, subject to his continuous service.
Immunocore Holdings plc reported insider transactions by Chief HR Officer Tina Amber St Leger. On February 18, 2026, she completed an open-market sale of 1,000 Ordinary Shares at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to satisfy income tax liabilities from restricted stock unit vesting.
On February 17, 2026, 2,119 Restricted Share Units were exercised and converted into 2,119 Ordinary Shares at no cost, with each RSU representing one Ordinary Share. After these transactions, she directly held 1,119 Ordinary Shares and 6,357 RSUs.
Immunocore Holdings plc’s Head of R&D, David M. Berman, reported RSU vesting, share issuance and a related tax sale. On February 17, 2026, he exercised 11,824 Restricted Share Units, receiving the same number of Ordinary Shares at a $0.00 exercise price.
On February 18, 2026, he conducted an open-market sale of 5,965 Ordinary Shares at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to satisfy income tax liabilities from RSU vesting. After these transactions, he directly held 5,859 Ordinary Shares and 35,473 RSUs. Each RSU and each American Depositary Share represents one Ordinary Share.
Immunocore plc reported planned insider stock sales via Form 144. The filing lists multiple proposed disposals of American Depositary Receipts (ADRs) by David Berman on dates in November and December 2025, with individual ADR quantities and aggregated dollar values shown for each sale date.